What question did this study set out to answer?

The study aims to identify and promote effective therapies for long COVID, also known as post-acute sequelae of COVID-19.

May 16, 2026Open Access

Towards biology-informed therapies for long COVID

Read Full Paperexternally

Key Points

The study aims to identify and promote effective therapies for long COVID, also known as post-acute sequelae of COVID-19.
Analysis of current interventional trials focusing on long COVID therapies.
Review of CDC estimates on long COVID prevalence and impact.
Assessment of the effectiveness of proposed disease-modifying therapies.
Approximately 2.8% to 4.4% of US adults are estimated to experience long COVID.
Less than 3% face significant day-to-day activity limitations due to the condition.
No approved and broadly effective therapies are available for treating this debilitating condition.

Abstract

The US Centers for Disease Control and Prevention estimates between 2.8% and 4.4% of adults in the USA are currently living with post-acute sequelae of COVID-19 (PASC; or long COVID) and that between 1.7% and 2.9% of US adults face substantial limitations in day-to-day activities due to PASC. Yet, despite hundreds of registered interventional trials aimed at addressing PASC, as of May, 2026, we still lack approved and broadly effective disease-modifying therapies for this debilitating condition.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

eBioMedicine

Journals

EBioMedicine

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Towards biology-informed therapies for long COVID

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study